A Phase 1/2 interventional study of TMB-365/TMB-380 in HIV-1-infection, sponsored by TaiMed Biologics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-10-22.
Sponsored by TaiMed Biologics Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 24 weeks.
This study is a phase 1b / 2 adaptive open-label dose escalation study of the combination of TMB-365 and TMB-380. This adaptive study design will be comprised of Sentinel Groups (N=10) and Core Groups (N=20). Safety and pharmacokinetic (PK) data obtained from Sentinel group participants will guide the conduct of Core Group execution.
Participants will be HIV-infected and suppressed for at least 6 months on continuous daily oral combination antiretroviral therapy (cART). Continuous is defined as no more than 3 consecutive days of missed cART. There are three doses of each antibody being explored, 2400 mg, 3200 mg, and 4800 mg.
Sentinel Groups Sentinel Groups will be comprised of 10 cART suppressed HIV-1 infected volunteers who receive a single IV dose of the combination of TMB-365 and TMB-380 while continuing cART.
Sentinel Group 1 will be dosed with 2400 mg of each antibody and will continue daily oral cART throughout the screening, infusion, and post-infusion observation period of 12 and be assessed for safety and pharmacokinetics.
Sentinel group 2 will dose both antibodies at 3200 mg. The third sentinel group will dose both antibodies at 4800 mg.
Criteria for safety of a dose of either TMB-365 or TMB-380 include:
i) No SAEs probably or definitely due to TMB-365 or TMB-380 ii) No more than one Grade 3 or Grade 4 adverse event probably or definitely related to TMB-365 or TMB-380 at any dose level.
Toxicity evaluations will be guided by the DAIDS Table for Grading Severity of Adult and Pediatric Adverse Events Version 2.1. The Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0 scale will be used for assessment of any infusion reactions, or anaphylactic events.
PK targets:
i. TMB-365: serum levels >0.3 μg/mL ii. TMB-380: serum levels >65 μg/mL Should a dose of either antibody prove safe and at least 80% of subjects studied in a given Sentinel dose group meet specified safety and PK criteria, then a Core group of 20 subjects will be enrolled and treated with that dose of TMB-365 and TMB-380 as a stand-alone complete maintenance regimen for 24 weeks.
Safety must be established prior to any request for dose escalation to the next higher Sentinel dose group. A review of 14-day safety data in 7 of 10 subjects after infusion must be available for review prior to any request for dose escalation. Dose escalation may only occur with the approval of an independent Data Monitoring Committee (DMC).
The maximum dose of TMB-365 and TMB-380 that will be tested in Sentinel groups is 4800 mg.
The first 3 subjects in each Sentinel group will be treated at designated sites selected for demonstration of expertise in the use of monoclonal antibody therapy. Subjects will remain at the study site for 3 hours post-infusion for monitoring of vital signs every 15 minutes beginning 15 minutes prior to the infusion of TMB-365 and TMB-380 as well as observation for the presence of infusion reactions. Should the infusions be well tolerated and no Grade 3 or 4 AEs, or SAE's occur due to study drugs within 7 days of infusion, then the remaining 7 subjects in that group may be recruited/treated. These subjects will remain at study sites for 1 hour post-infusion for monitoring of vital signs and the presence of infusion reactions.
Core Group Subjects There will be one Core Group comprised of 40 cART suppressed HIV-1 infected volunteers and will receive multiple IV doses of the combination of TMB-365 and TMB-380 as a stand-alone maintenance regimen for 24 weeks. Oral cART will be restarted in the clinic at the Week 24 visit.
Core group participants will complete the study at Day 196, 4 weeks after reinstituting oral cART. Sentinel group participants at the same dosing level may be enrolled in a Core group if infusions are well tolerated and the subject is willing to discontinue oral cART.
Core Group study group 1 will begin with the doses of each antibody that prove safe and meet PK targets.
Regimen in Core Group participants based on PK modeling include:
TMB-365: 4800 mg q 8 weeks. TMB-380: 4800 mg q 8weeks. Sentinel Group participants that wish to participate in Core Groups must repeat all screening procedures including signing a second Informed Consent Form.
TaiMed Biologics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Participants must meet all of the following criteria to be included in the study:
Laboratory values obtained within 30 days prior to the first dose:
Females of , sexually active with a male sex partner, must agree to use one effective method of from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Females of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not (at least one year without menses), and are not otherwise sterile by medical evaluation.
-
Exclusion Criteria:
Participants having or meeting any of the following conditions or characteristics will be excluded from the study:
Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens and those being treated with regimens containing either ibalizumab, enfuvirtide, maraviroc, and fostemsavir. Note that a change in treatment regimen for intolerance does not meet criteria for virologic failure.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
Drug: TMB-365/TMB-380
10 HIV-1 infected subjects will receive one infusion of 3200 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
Drug: TMB-365/TMB-380
10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.
Drug: TMB-365/TMB-380
20 HIV-1 infected subjects will receive 4800 mg infusions of each antibody, TMB-365 and TMB-380 every 8 weeks and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.
Drug: TMB-365/TMB-380
Monoclonal antibodies to be given intravenously
Also known as: TMB-380 is also known as VRC07-523-LS
Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)
Grade 3, Grade 4, Serious Adverse reactions related to TMB-365 and TMB-380 infusions
Time frame: 12 weeks (Sentinel Group 1), 16 weeks (Sentinel Group 2, 3), 28 weeks (Core Group)
Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)
In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-365 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.
Time frame: Week 8
Pharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)
Core Group participants received 4800 mg every 8 weeks.TMB-365 concentrations were measured using a validated ELISA. Trough concentrations are reported.
Time frame: Week 8, 16, and 24
Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)
In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-380 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.
Time frame: Week 8
Pharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)
Core Group participants received 4800 mg every 8 weeks.TMB-380 concentrations were measured using a validated ELISA. Trough concentrations are reported.
Time frame: Weeks 8, 16, and 24
Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)
Plasma HIV-1 level below 50 copies/mL in study subjects at week 24 during maintenance therapy with TMB-365/TMB-380 infusions in Core Subjects only.
Time frame: Week 24
Resistance to TMB-365 and TMB-380 (Core)
Phenotype and genotype of HIV-1 variants in study subjects who fail to maintain antiviral response on infusions of TMB-365 and TMB-380
Time frame: 24 weeks
| Milestone | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 21 |
| Completed | 10 | 10 | 9 | 18 |
| Not completed | 0 | 0 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
Grade 3, Grade 4, Serious Adverse reactions related to TMB-365 and TMB-380 infusions
| Participants | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 |
|---|---|---|---|---|
| Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core) | 0 | 0 | 0 | 0 |
In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-365 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.
| mcg/mL | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 |
|---|---|---|---|
| Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel) | 0.50 ± 1.23 | 1.91 ± 3.19 | 15.13 ± 13.45 |
Core Group participants received 4800 mg every 8 weeks.TMB-365 concentrations were measured using a validated ELISA. Trough concentrations are reported.
| mcg/mL | Core Group |
|---|---|
| Week 8 pre-dose concentration | 29.54 ± 30.18 |
| Week 16 pre-dose concentration | 29.12 ± 31.25 |
| Week 24 trough concentration | 29.11 ± 35.94 |
Phenotype and genotype of HIV-1 variants in study subjects who fail to maintain antiviral response on infusions of TMB-365 and TMB-380
| Participants | Core Group 1 |
|---|---|
| Resistance to TMB-365 and TMB-380 (Core) | 0 |
In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-380 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.
| mcg/mL | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 |
|---|---|---|---|
| Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel) | 59.59 ± 14.59 | 63.05 ± 16.47 | 86.43 ± 24.09 |
Core Group participants received 4800 mg every 8 weeks.TMB-380 concentrations were measured using a validated ELISA. Trough concentrations are reported.
| mcg/mL | Core Group 1 |
|---|---|
| Week 8 pre-dose concentration | 83.72 ± 25.13 |
| Week 16 pre-dose concentration | 91.48 ± 21.93 |
| Week 24 trough concentration | 107.12 ± 28.44 |
Plasma HIV-1 level below 50 copies/mL in study subjects at week 24 during maintenance therapy with TMB-365/TMB-380 infusions in Core Subjects only.
| Participants | Core Group 1 |
|---|---|
| Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core) | 16 |
Collected over Adverse events were collected for the duration of the study which included a screening period of 6 weeks, 12 weeks for the 2400 mg and 3200 mg single dose group, 16 weeks for the 4800 mg single dose group, and 28 weeks for the 4800 mg multiple dose group (infusions for 24 weeks and 4 weeks of follow up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sentinel Group 1 | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Sentinel Group 2 | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Sentinel Group 3 | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Core Group 1 | 0/21 (0%) | 0/21 (0%) | 14/21 (66.7%) |
| Event | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 |
|---|---|---|---|---|
| COVID-19Infections and infestations | 3/10 | 1/10 | 0/10 | 1/21 |
| fatigueGeneral disorders | 1/10 | 2/10 | 0/10 | 4/21 |
| hypersensitivityImmune system disorders | 0/10 | 2/10 | 0/10 | 0/21 |
| upper respiratory infectionInfections and infestations | 0/10 | 1/10 | 2/10 | 2/21 |
| rashSkin and subcutaneous tissue disorders | 0/10 | 1/10 | 1/10 | 3/21 |
| headacheNervous system disorders | 0/10 | 1/10 | 0/10 | 3/21 |
| papulesSkin and subcutaneous tissue disorders | 1/10 | 1/10 | 0/10 | 0/21 |
| syphilisInfections and infestations | 0/10 | 0/10 | 1/10 | 0/21 |
| streptococcal pharyngitisInfections and infestations | 0/10 | 0/10 | 1/10 | 0/21 |
| eczemaSkin and subcutaneous tissue disorders | 1/10 | 0/10 | 0/10 | 0/21 |
Study subjects are all HIV-infected, cART treated and suppressed on therapy for at least 6 months
| Age, Continuous(years) | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 | Total |
|---|---|---|---|---|---|
| Mean | 44.5 ± 7.9 | 43.1 ± 12.1 | 44 ± 10.1 | 49.3 ± 12.4 | 46.1 ± 10.8 |
| Sex: Female, Male(Participants) | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 | Total |
|---|---|---|---|---|---|
| Female | 0 | 1 | 1 | 1 | 3 |
| Male | 10 | 9 | 9 | 20 | 48 |
| Race (NIH/OMB)(Participants) | Sentinel Group 1 | Sentinel Group 2 | Sentinel Group 3 | Core Group 1 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 2 | 5 | 11 |
| White | 7 | 6 | 7 | 14 | 34 |
| More than one race | 1 | 0 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Nov 2024, 28 months.
Results were first posted in Oct 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TaiMed Biologics Inc.